Bluetongue vaccines: the past, present and future.

Bluetongue (BT) is a noncontagious and arboviral disease of both domestic and wild ruminants. The disease is enzootic in areas where reservoirs (cattle and wild ruminants) and vectors exist for the BT virus (BTV). A total of 24 BTV serotypes have been recognized worldwide. The major control measures include restriction of animal movement, vector control applying insecticides, slaughter of infected animals and vaccination. Prophylactic immunization of sheep against BT is the most practical and effective control measure to combat BT infection. At present, attenuated vaccines are used in the Republic of South Africa, the USA and other countries. However, EU countries were using attenuated vaccines, only recently shifting to inactivated vaccines owing to their safety and efficacy. In India, inactivated vaccines are in experimental stages and are expected to be on the market shortly. Inactivated vaccines generate serotype-specific long-lasting protective immunity after two injections, and may help in controlling epidemics. Differentiating infected from vaccinated animals (DIVA) is theoretically possible with inactivated vaccines but has not yet been developed, whereas the attenuated live vaccines are not candidates for DIVA. Attenuated live vaccines are efficacious but safety issues are of great concern. New-generation vaccines (subunit, virus-like particles, core-like particles and vectored) can be employed for DIVA. Recombinant vaccines, which generate cross-protection against multiple BTV serotypes, have great potential in BT vaccine regimens. Furthermore, new-generation vaccines are safe and efficacious experimentally, but large-scale field trials are warranted. Alternative areas, such as antivirals, siRNA, interferon and nanotechnology, may be of future use in the control of BT. We give an overview of BT vaccines, starting from conventional to recent developments, and their feasibility in controlling BT infection.

The current status of sheep pox disease.

Sheep are the moving banks of shepherds and their economic contribution in terms of meat, wool and skin/hide is immense. Various infectious diseases jeopardize the optimum productivity; among which sheep pox is more important as the disease restricts the export of sheep and their products besides other economic losses. Although, clinical signs are indicative of the disease but a laboratory confirmation is necessary for unequivocal diagnosis and studying epidemiology. The causative agent, sheep pox virus (SPV), is antigenically and genetically closely related to goat pox virus (GPV) and lumpy skin disease virus (LSDV), the other members of the genus capripox virus. In some countries, SPV and GPV are cross infective to small ruminants posing problem in diagnosis and epidemiology. However, recent studies have showed that the viruses are phylogenetically distinct and can be differentiated by molecular tools. Prophylaxis using attenuated vaccines is the choice of control measure as the immunity is long lasting. Detailed information on isolation, identification, pathology, epidemiology, diagnosis and prophylaxis would not only help in updating the knowledge of scientific fraternity but will be useful to the policy makers in order to formulate appropriate measures for control and eradication of the disease. This synthesis is to present an up-to-date review of the disease and its control to provide the reader with an overview of the problem.

An epidemiological study of sheep pox infection in Karnataka State, India.

Analysis of retrospective quantitative sheep pox epidemiological data from the Government Animal Husbandry Department, Karnataka, India, covering 24 years revealed significant information on sheep pox. The state has a dense sheep population including some valuable breeds. Data revealed the endemicity of the disease: there were a considerable number of outbreaks and attacks, high mortality and case fatality rates and low immunisation coverage. None of the years studied were free from infection. Temporally, the disease was most prevalent between November and May. Spatially, the disease was recorded in 19 out of 27 districts; in some of these districts sheep pox was highly endemic, in some it was endemic at low levels and in the remaining districts outbreaks occurred sporadically. Environmental factors influenced disease occurrence. Vaccine production met only one tenth of the requirement, and its peak utilisation was in the dry season.

A classical live attenuated vaccine for sheep pox.

A classical live attenuated sheep pox vaccine was prepared using the Ranipet strain of sheep pox virus (SPV) at the 50th passage in a secondary lamb testicular cell system. The TCID50 and RD50 were 10(9.63)/ml and 10(9.51)/ml. respectively. The SID50 of SPV challenge virus was 10(5)/ml. The vaccine was found to have no adverse effects in laboratory animals, and was safe and effective in SPV seronegative lambs. In the field, 660 sheep were vaccinated with an immunizing dose containing 1 x 10(2) TCID50. Randomly selected vaccinated sheep mounted good cell-mediated immunity and humoral responses as measured by glucose utilization test and serum neutralization test, respectively, for the study period of 6 months.